Search
Vaccines Treatment Options
A collection of 953 research studies where Vaccines is the interventional treatment. These studies are located in the United States . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
241 - 252 of 953
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
Completed
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine (\[Prevnar 20™ / APEXXNAR™\]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Central Research Associates ( Site 0067), Birmingham, Alabama +111 locations
Conditions: Pneumococcal Infection
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Completed
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS dTM-AS03 vaccine, in adults 18 years of age and older.
A total of approximately 21 046 participants are planned to be enrolled (5080 per study intervention group in Stage 1 and 5443 per study intervention group in Stage 2).
Initial, do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: AES - DRS - Simon Williamson Clinic, PC - Birmingham Site Number : 8400004, Birmingham, Alabama +85 locations
Conditions: COVID-19
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Completed
This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
10/10/2024
Locations: UCSF Children's Hospital, San Francisco, California +8 locations
Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
Completed
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
10/10/2024
Locations: Birmingham Pediatric Associates Site Number : 8400026, Birmingham, Alabama +69 locations
Conditions: Healthy Volunteers (Meningococcal Infection)
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
Recruiting
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
Completed
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/27/2024
Locations: Meridian Clinical Research (Sioux City, IA), Sioux City, Iowa +10 locations
Conditions: Zika Virus
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
Completed
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and compare the immunogenicity between an intramuscular monovalent inactivated influenza A/H7N9 virus vaccine given with and without AS03 adjuvant, and an intramuscular unadjuvanted monovalent inactivated influenza A/H3N2v virus vaccine. The primary objectives are (1) assessi... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
09/26/2024
Locations: Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville, Tennessee
Conditions: Avian Influenza, H1N1 Influenza, Influenza
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/26/2024
Locations: Accel Research Sites-Birmingham Clinical Research Unit, Birmingham, Alabama +19 locations
Conditions: Pneumococcal Vaccines
Vaccine Responses in Cancer
Recruiting
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Gender:
ALL
Ages:
All
Trial Updated:
09/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Viral Vaccines
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
Recruiting
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from part... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/17/2024
Locations: UConn Health, Center On Aging, Farmington, Connecticut
Conditions: Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
Completed
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects aga... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/11/2024
Locations: Huntington Hospital, Pasadena, California
Conditions: Covid19, Vaccine Reaction
BCG Vaccine for Health Care Workers as Defense Against COVID 19
Completed
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo stu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +5 locations
Conditions: Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
241 - 252 of 953